UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported):  January 20, 2006

 

The Medicines Company

(Exact Name of Registrant as Specified in Charter)

 

Delaware

 

000-31191

 

04-3324394

(State or Other Jurisdiction
of Incorporation)

 

(Commission
File Number)

 

(IRS Employer
Identification No.)

 

 

 

 

 

8 Campus Drive
Parsippany, New Jersey

 

07054

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (973) 656-1616

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨                                    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨                                    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨                                    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨                                    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

Item 1.01.  Entry into a Material Definitive Agreement

 

After considering information on total compensation for each executive officer of The Medicines Company (the “Company”) and a survey of comparative data provided by an outside compensation consultant, the Compensation Committee of the Board of Directors of the Company established the following base salaries for the Company’s executive officers for 2006, effective as of January 1, 2006:

 

 

 

2006 Annual Base Salary

 

Clive A. Meanwell
Chief Executive Officer

 

$

516,000

 

John P. Kelley
President and Chief Operating Officer

 

$

400,000

 

Steven H. Koehler
Senior Vice President and Chief Financial Officer

 

$

310,000

 

Paul M. Antinori
Vice President and General Counsel

 

$

260,000

 

John D. Richards
Vice President

 

$

215,519

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

THE MEDICINES COMPANY

 

 

 

 

Date: January 25, 2006

By:

/s/ Steven H. Koehler

 

 

 

Steven H. Koehler

 

 

Senior Vice President and Chief Financial Officer

 

2